Brain Aneurysm
Also known as: Berry aneurysm, Cerebral aneurysm, Intracranial aneurysm
Methodology & AI Transparency ⓘ
Brain Aneurysm Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: A brain aneurysm is an abnormal bulge or "ballooning" in the wall of an artery in the brain.
- 2 Real-world patient consensus: Clinical coding for Brain Aneurysm uses ICD-10 I67.1 across Blood Pressure specialty care.
- 3 Typical cash cost range: Clinicians assessing Brain Aneurysm focus on elevated systemic vascular in Brain Aneurysm (I67.1: resistance) and targeted history.
- 4 Top reported side effects / signs: Longitudinal Brain Aneurysm monitoring tracks Urine Albumin-to-Creatinine Ratio [Brain Aneurysm I67.1] toward < 15 mg/g (I67.1).
Ask our AI Specialists anything about Brain Aneurysm
What Is Brain Aneurysm?
A brain aneurysm is an abnormal bulge or "ballooning" in the wall of an artery in the brain. They are sometimes called berry aneurysms because they are often the size of a small berry. Most brain aneurysms produce no symptoms until they become large, begin to leak blood, or burst. If a brain aneurysm presses on nerves in your brain, it can cause signs and symptoms. These can include: A droopy eyelid Double vision or other changes in vision Pain above or behind the eye A dilated pupil Numbness or weakness on one side of the face or body Treatment depends on the size and location of the aneurysm, whether it is infected, and whether it has burst.
Pathophysiology, Underlying Causes & Clinical Presentation
In Brain Aneurysm (I67.1), physiological disruption stems from elevated systemic vascular in Brain Aneurysm (I67.1: resistance), Cross-referenced with NIH MeSH (Intracranial Aneurysm), informing High Blood Pressure & Vascular Health protocols that track Home Seated Blood in Brain Aneurysm (I67.1: Pressure) (< 120/75 mmHg (I67.1)).
Common Symptoms & Clinical Signs
- • Double vision or other changes in vision
- • Pain above or behind the eye
- • Presentation of Brain Aneurysm (I67.1): calf cramping or in Brain Aneurysm (I67.1: claudication triggered by)
- • Secondary Brain Aneurysm clinical sign: localized extremity swelling, in Brain Aneurysm (I67.1: warmth, or venous)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Brain Aneurysm Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | I67.1 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | High Blood Pressure & Vascular Health | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Urine Albumin-to-Creatinine Ratio [Brain Aneurysm I67.1] | < 15 mg/g (I67.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Home Seated Blood in Brain Aneurysm (I67.1: Pressure) | < 120/75 mmHg (I67.1) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Ankle-Brachial Index (ABI) [Brain Aneurysm I67.1] | 1.00 – 1.30 (I67.1) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Brain Aneurysm
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Gadoterate Meglumine Dotarem, Clariscan • RxCUI RXN-70436123-1767 | Gadolinium-based Contrast Agent | 93% | $0.8000 | $ 40.90 /mo |
| Flortaucipir F-18 Tauvid • RxCUI RXN-00021220-1770 | FDA Prescription Therapeutic Agent | 75% | $0.8300 | $ 42.12 /mo |
| Lomustine Gleostine • RxCUI 197894 | Alkylating Drug | 83% | $0.5700 | $ 31.58 /mo |
| Florbetapir F 18 Amyvid • RxCUI RXN-00021200-1728 | Radioactive Diagnostic Agent | 85% | $2.8200 | $ 122.71 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Brain Aneurysm)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| New Insights on Three Low-Dose blood-pressure-lowering Agents in a Single Pill after: What a 1,670-Participant Study Found Among patients with intracerebral hemorrhage, treatment with a combination of three low-dose blood-pressure-lowering agents in a single pill, in addition to standard care, was associated with a lower incidence of recurrent... The New England journal of medicine • 2026-04-23 • Phase III Randomized Trial | N = 1,670 | 96/100 | PMID 42019018 ↗ |
| New Insights on Type 2 diabetes accelerates brain aging and cognitive decline: Complementary: What a 20,314-Participant Study Found The neurocognitive impact of T2DM suggests marked acceleration of normal brain aging. eLife • 2022-05-24 • Meta-Analysis | N = 20,314 | 94/100 | PMID 35608247 ↗ |
| New Insights on Brain Injury Outcomes after Adjuvant Erythropoietin Neuroprotection for Moderate: What a 414-Participant Study Found Adjuvant erythropoietin did not reduce the incidence of regional brain injury. Developmental neuroscience • 2024-01-15 • Phase III Randomized Trial | N = 414 | 93/100 | PMID 37906983 ↗ |
| Can This Approach Help? Inside the Latest Research on Combining Cognitive Training and Brain Stimulation: A Novel Approach to Address The initiation of antipsychotic therapy is a critical clinical window for early intervention to mitigate the long-term metabolic and psychiatric consequences of antipsychotic-induced weight gain. Early intervention in psychiatry • 2026-11-15 • Randomized Controlled Trial | Multi-cohort | 88/100 | PMID 42929065 ↗ |
| Can This Approach Help? Inside the Latest Research on Minimal Important Difference in N-Terminal Pro-Brain Natriuretic Peptide in lung Our results show the estimated MID for short-term NT-proBNP improvement in PAH and PH-ILD is remarkably similar at 48%. Chest • 2026-07-15 • Phase III Randomized Trial | Multi-cohort | 88/100 | PMID 41802593 ↗ |
Brain Aneurysm Patient Community & “People Like Me” Threads
Filter Brain Aneurysm community threads and patient logs by age, biological sex, dosage, and treatment duration.